Please find enclosed Earnings Call Transcript - Q1FY27

AI summary - Q1 FY27 revenue INR 7,119 Cr, +2% y-y (adjusted ~4% growth) - One India business grew 12% y-y; branded prescription up 15.4% - North America revenue $162M; Ventolin generic launched, ramp expected by FY end - EBITDA margin 16.7% excluding other income; PAT INR 789 Cr (11% of sales) - R&D spend INR 486 Cr (6.8% of revenue); net cash INR 9,494 Cr post dividend - South Africa private market grew 6.5%, tender business declined - U.S. pipeline includes 3 respiratory and 1 peptide launch; $1B exit revenue target maintained - Gross margin 62.5%, impacted by product mix, war costs, inventory charges - New CFO Dinesh Jain appointed; outgoing CFO Ashish Adukia thanked - Multiple analyst queries on U.S. launches and margin trajectory; mgmt expects margin improvement with new products